Novo Nordisk Still a Buy, But Patience May Be Needed -- Market Talk

Dow Jones
01-10

1340 GMT - Novo Nordisk is still a buy, but investors might need patience, Deutsche Bank analyst Emmanuel Papadakis writes. Novo Nordisk recently reported disappointing results of a closely watched clinical trial testing an experimental anti-obesity treatment. The bank lowers its share target price to 900 Danish kroner from 1,000 kroner to reflect the recent setback. It keeps its buy rating on the stock. Shares trade 0.7% higher at 634.60 kroner. (dominic.chopping@wsj.com)

 

(END) Dow Jones Newswires

January 10, 2025 08:41 ET (13:41 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10